INTRODUCTION
The Kazal-type inhibitor is a peptide of Mr 6200 isolated first from pancreatic tissue (Kazal et al., 1948 ).
This peptide is also called pancreatic secretory trypsin inhibitor (PSTI). Its role has been postulated to be the prevention of inadvertent proteolysis in the pancreas caused by premature activation of trypsinogen (Greene et al., 1966; Pubols et al., 1974) . Its inhibitory specificity has been shown to be very narrow, with strong inhibitory capacity only against pancreatic trypsin (Fritz et al., 1967) and acrosin (Huhtala, 1984) . A similar or identical inhibitor, called tumour-associated trypsin inhibitor (TATI), was recently identified and isolated from the urine of a patient with ovarian cancer . High concentrations of this inhibitor occur in ovarian tumour extracts, especially of the mucinous type (Halila et al., 1987) and in serum and urine of these patients (Halila et al., 1988) . This suggests that Kazal-type inhibitors have a physiological function outside the pancreas. Further evidence for an extrapancreatic role is the finding of TATI in pancreatectomized patients (Halila et al., 1985) , as well as elevated urine and serum levels of TATI in connection with severe infections (Huhtala et al., 1983) , after major surgery and severe trauma .
Proteinases and their inhibitors occur together (Strauli, 1980) . Therefore, the elevation of TATI in cancer and other extrapancreatic diseases can be expected to be associated with the expression of extrapancreatic proteinases reacting with this Kazal-type inhibitor.
To elucidate mechanisms for elevation of TATI in cancer and inflammation we have investigated the interaction between TATI and some serine proteinases involved in tumour invasion, inflammation, coagulation and fibrinolysis. For comparison we also studied the pancreatic enzymes trypsin and chymotrypsin.
MATERIALS AND METHODS
TATI was isolated from human urine and its concentration was determined by radioimmunoassay Laskowski & Kato (1980) . the method of Henderson (1972) , as modified by Bieth (1980) . The Km value of the enzyme-substrate reaction given by the manufacturer of the substrate was checked by using various substrate concentrations.
RESULTS
All the serine proteinases studied were inhibited by TATI. However, large differences in the affinity of TATI for various proteinases were observed. Only trypsin, plasmin and urokinase had Ki values indicating strong or moderate affinity (Table 1 ). The affinity for trypsin was about 160-fold that of plasmin, which had the next highest affinity.
The comparison of TATI concentrations causing 50 inhibition of various enzymes gives some indication of which enzymes will be inhibited by physiological concentrations of TATI (Table 1) . Nearly complete inhibition of the amidolytic activity of 19 nM-trypsin was obtained with 19 nM-TATI (Fig. 1) , which corresponds to a 1: 1 molar binding ratio. (Fig. 2 a) and chymotrypsin ( Fig. 2c) at TATI concentrations ranging from 0.45 to 6 /tM and that of tPA from 8 to 15 /M (Fig.  2e) . The results are summarized in Table 1 .
Compared with TATI, SBTI and aprotinin were equally potent inhibitors of trypsin, but their inhibitory activity against plasmin (Fig. 2a) , chymotrypsin (Fig.  2 c) and kallikrein (Fig. 2 d) (Huhtala et al., 1983; Haglund et al., 1986; Halila et al., 1987) .
The reaction between Kazal-type inhibitors and plasminogen activators has, to our knowledge, not been studied before. Earlier studies on the reaction between the pancreatic Kazal inhibitor (PSTI) and plasmin indicated that there is no inhibition (Fritz et al., 1967; Greene et al., 1976) . The discrepancy between these results and those of the present study could possibly be explained by differences in the assay conditions, e.g. enzyme and substrate concentrations.
The physiological concentrations of TATI in serum are below 20 ,g/l, corresponding to 3.2 nM Haglund et al., 1986) . This is about 1000-10000-fold less than the concentrations (3.6-56,UM) of the major proteinase inhibitors, x1-proteinase inhibitor, (0) and TATI (@) by using S-2586; (d) kallikrein (26 nM) by SBTI (Ol), aprotinin (0) and TATI (@) by using S-2302; and (e) tPA (215 nM) by TATI (@) with S-2222. All substrate concentrations were 70 /LM in the assay mixture. The activity obtained without inhibitors was set at 100%.
az-antichymotrypsin and a2-macroglobulin (Laskowski & Kato, 1980) . Although the serum concentrations of TATI associated with cancer may be up to 230 nM (Haglund et al., 1986 ), this will hardly play a major role in proteinase inhibition in the circulation. Locally TATI might be of physiological importance in various tissues. Evidence for local production was provided by the finding of TATI immunoreactivity in tumour tissues Murata et al., 1983; Halila et al., 1987) . The main sources of the Kazal inhibitors known so far are the pancreas and mucinous ovarian tumours (Halila et al., 1987 (McKeehan et al., 1986) , but production by normal liver has not been demonstrated so far.
Tumour invasion is associated with expression of plasminogen activators causing a local increase in plasmin levels (Dano et al., 1985) . Our results show that both plasmin and urokinase are inhibited by TATI at concentrations occurring in vivo. Locally TATI could thus be involved in the control of their proteolytic activity, and activation of these proteinases could be a factor triggering the elevation of TATI.
Although activation of urokinase and plasmin could induce the expression of TATI in cancer patients, these enzymes do not need to be the only or even the major inducers. We have recently identified a proteinase which reacts strongly to TATI in mucinous ovarian tumours . So far we have observed this proteinase only in mucinous ovarian tumours, which also contain high levels of TATI. Therefore, other proteinases, e.g. plasmin and urokinase may be responsible for the elevation of TATI in other forms of cancer.
